# CSGALNACT2

## Overview
CSGALNACT2 is a gene that encodes the enzyme chondroitin sulfate N-acetylgalactosaminyltransferase 2, a type II membrane protein primarily located in the Golgi apparatus. This enzyme is integral to the biosynthesis of chondroitin sulfate, a vital component of the extracellular matrix, by facilitating the elongation of chondroitin and chondroitin sulfate chains through the transfer of N-acetylgalactosamine to glucuronic acid residues (Sato2003Differential). CSGalNAcT-2 is particularly active in the synthesis of sulfated chondroitin polymers, such as CS-A and CS-B, and is ubiquitously expressed across various tissues, with notable expression in the small intestine, leukocytes, and spleen (Sato2003Differential). The enzyme's activity is crucial for maintaining the structural integrity and function of the extracellular matrix, influencing cellular processes such as adhesion, migration, and signal transduction (Sato2003Differential).

## Function
CSGALNACT2 encodes the enzyme chondroitin sulfate N-acetylgalactosaminyltransferase 2, which plays a crucial role in the biosynthesis of chondroitin sulfate (CS), a key component of the extracellular matrix. This enzyme is involved in the elongation of chondroitin and chondroitin sulfate chains by transferring N-acetylgalactosamine (GalNAc) to glucuronic acid (GlcA) residues, forming the repeating disaccharide units of CS (Sato2003Differential). CSGalNAcT-2 is particularly active in the elongation of sulfated chondroitin polymers, such as CS-A and CS-B, indicating its preference for sulfated substrates (Sato2003Differential).

The enzyme is a type II membrane protein located in the Golgi apparatus, where it participates in the synthesis of glycosaminoglycans (GAGs) (Sato2003Differential). CSGalNAcT-2 is ubiquitously expressed across various tissues, with high expression levels in the small intestine, leukocytes, and spleen, suggesting its significant role in these tissues (Sato2003Differential). The activity of CSGalNAcT-2 is essential for maintaining the structural integrity and function of the extracellular matrix, influencing cellular processes such as adhesion, migration, and signal transduction (Sato2003Differential).

## Clinical Significance
CSGALNACT2 is implicated in several diseases and conditions due to its altered expression or mutations. In ovarian cancer, CSGALNACT2 is significantly downregulated, acting as a tumor suppressor by inhibiting cancer cell migration and invasion through the MAPK/ERK pathway. This downregulation is associated with poor prognosis and reduced response to immunotherapy in ovarian cancer patients (Ma2023CSGALNACT2). In contrast, high expression of CSGALNACT2 in colon and rectum adenocarcinomas correlates with shorter overall survival, indicating a complex role in different cancer types (Ma2023CSGALNACT2).

Beyond cancer, abnormal expression of CSGALNACT2 is linked to other conditions such as osteoarthritis of the knee, atherosclerosis, pediatric high-grade glioma, and multiple myeloma (Ma2023CSGALNACT2). The gene's involvement in these diseases suggests its role in cellular processes like proliferation, migration, and differentiation, which are critical in both cancer progression and other pathological conditions. The study of CSGALNACT2 highlights its potential as a prognostic biomarker and therapeutic target, particularly in ovarian cancer, where its expression levels could guide treatment strategies (Ma2023CSGALNACT2).

## Interactions
CSGALNACT2 interacts with the capsid protein VP2 of the infectious bursal disease virus (IBDV). This interaction was identified using a yeast two-hybrid system and confirmed through co-immunoprecipitation assays. The interaction suggests that CSGALNACT2 may play a role in the viral replication process by interacting with VP2 in the Golgi apparatus, as evidenced by the co-localization of CSGALNACT2 with GOLGA2, a Golgi marker protein (Zhang2015Chondroitin).

CSGALNACT2 is also involved in the biosynthesis of glycosaminoglycans, specifically chondroitin sulfate (CS). It catalyzes the transfer of N-acetylgalactosamine to a tetrasaccharide substrate, a critical step in CS chain synthesis. While CSGALNACT2 does not show specific interactions with other proteins or nucleic acids in this context, it is more efficient in this transfer than the CHSY3/CHPF complex, indicating its significant role in CS polymerization (Sammon2023Molecular).

In ovarian cancer, CSGALNACT2 is linked to the MAPK/ERK signaling pathway, where its expression is associated with the modulation of this pathway through DUSP1. However, specific physical interactions with other proteins or nucleic acids in this context are not detailed (Ma2023CSGALNACT2).


## References


[1. (Zhang2015Chondroitin) Lizhou Zhang, Xiangang Ren, Yuming Chen, Yulong Gao, Nian Wang, Zhen Lu, Li Gao, Liting Qin, Yongqiang Wang, Honglei Gao, Kai Li, Lili Jiang, Hongyu Cui, Changjun Liu, Yanping Zhang, Xiaole Qi, and Xiaomei Wang. Chondroitin sulfate n-acetylgalactosaminyltransferase-2 contributes to the replication of infectious bursal disease virus via interaction with the capsid protein vp2. Viruses, 7(3):1474–1491, March 2015. URL: http://dx.doi.org/10.3390/v7031474, doi:10.3390/v7031474. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/v7031474)

[2. (Ma2023CSGALNACT2) Mingjun Ma, Chao Wang, Meixuan Wu, Sijia Gu, Jiani Yang, Yue Zhang, Shanshan Cheng, Shilin Xu, Minghai Zhang, Yongsong Wu, Yaqian Zhao, Xiu Tian, Dominic Chih-Cheng Voon, Chiaki Takahashi, Jindan Sheng, and Yu Wang. Csgalnact2 restricts ovarian cancer migration and invasion by modulating mapk/erk pathway through dusp1. Cellular Oncology, 47(3):897–915, December 2023. URL: http://dx.doi.org/10.1007/s13402-023-00903-9, doi:10.1007/s13402-023-00903-9. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13402-023-00903-9)

[3. (Sammon2023Molecular) Douglas Sammon, Anja Krueger, Marta Busse-Wicher, Rhodri Marc Morgan, Stuart M. Haslam, Benjamin Schumann, David C. Briggs, and Erhard Hohenester. Molecular mechanism of decision-making in glycosaminoglycan biosynthesis. Nature Communications, October 2023. URL: http://dx.doi.org/10.1038/s41467-023-42236-z, doi:10.1038/s41467-023-42236-z. This article has 6 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-023-42236-z)

[4. (Sato2003Differential) Takashi Sato, Masanori Gotoh, Katsue Kiyohara, Tomohiro Akashima, Hiroko Iwasaki, Akihiko Kameyama, Hideo Mochizuki, Toshikazu Yada, Niro Inaba, Akira Togayachi, Takashi Kudo, Masahiro Asada, Hideto Watanabe, Toru Imamura, Koji Kimata, and Hisashi Narimatsu. Differential roles of twon-acetylgalactosaminyltransferases, csgalnact-1, and a novel enzyme, csgalnact-2. Journal of Biological Chemistry, 278(5):3063–3071, January 2003. URL: http://dx.doi.org/10.1074/jbc.m208886200, doi:10.1074/jbc.m208886200. This article has 90 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m208886200)